Search results
Showing 851 to 900 of 1226 results for nice quality standards or clinical guidelines
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves using heated water vapour to destroy some of the prostate tissue.
View recommendations for IPG625Show all sections
Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (IPG749)
Evidence-based recommendations on laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. This involves placing a ring of beads outside of the food pipe, just above the stomach. Magnets inside the beads hold them together to keep the food pipe closed but are weak enough to move apart to allow food or liquid to be swallowed. The aim is to prevent acid reflux.
View recommendations for IPG749Show all sections
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .
Awaiting development [GID-QS10094] Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy?...
In development [GID-QS10113] Expected publication date: TBC
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)
Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)
NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.
View recommendations for IPG783Show all sections
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Biographies and registered interests for members of the Technology Appraisal Committee A
An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing
Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.
View recommendations for IPG770Show all sections
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
View recommendations for TA494Show all sections
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Embed NICE content in your digital products and services with our syndication API
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .
NICE research projects and partners.
NICE has developed a medtech innovation briefing (MIB) on the Neo Pedicle Screw System for spinal fusion surgery .
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Immunoscore for predicting risk of colon cancer relapse (MIB269)
NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .
In development [GID-QS10186] Expected publication date: TBC
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
KODEX-EPD for cardiac imaging during ablation of arrhythmias (MIB260)
NICE has developed a medtech innovation briefing (MIB) on KODEX-EPD for cardiac imaging during ablation of arrhythmias .
Maximal cytoreductive surgery for advanced ovarian cancer (IPG757)
Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.
View recommendations for IPG757Show all sections
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.